Fax: (713) 794-4297
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Article first published online: 11 MAR 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 11, pages 2482–2490, 1 June 2009
How to Cite
Quintás-Cardama, A., Kantarjian, H., Ravandi, F., O'Brien, S., Thomas, D., Vidal-Senmache, G., Wierda, W., Kornblau, S. and Cortes, J. (2009), Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer, 115: 2482–2490. doi: 10.1002/cncr.24257
- Issue published online: 20 MAY 2009
- Article first published online: 11 MAR 2009
- Manuscript Accepted: 4 NOV 2008
- Manuscript Revised: 27 OCT 2008
- Manuscript Received: 17 SEP 2008
- bleeding diathesis;
- chronic myelogenous leukemia;
- risk factors;
The most frequent nonhematologic side effects associated with dasatinib therapy in patients with chronic myeloid leukemia (CML) are gastrointestinal, rash, and fluid retention syndromes. However, bleeding has been observed in some patients receiving dasatinib. In the current study, the authors investigated the risk factors and management of bleeding associated with dasatinib therapy for CML after imatinib failure.
The bleeding episodes associated with dasatinib therapy in 138 patients with CML who were consecutively treated at the study institution in clinical trials were evaluated.
Bleeding occurred in 32 (23%) patients (grade ≥3 in 9 [7%] patients [according to National Cancer Institute Common Toxicity Criteria]), including in 12% of patients treated in chronic phase, 31% of patients treated in accelerated phase (AP), and 35% of patients treated in blast phase (BP) (P = .02). The majority of episodes (81%) affected the gastrointestinal tract. Basic coagulation studies were normal in 97% of patients who developed bleeding complications. Although 37% of episodes occurred with platelet counts >100 × 109/L, multivariate analysis identified thrombocytopenia and advanced phase CML as risk factors for bleeding. A trend toward an increased risk with a twice‒daily schedule was observed (P = .17). Management included dasatinib interruption for a median of 17 days (range, 3-51 days) in 47%, of patients and transfusions in 72% of patients.
Bleeding occurs during dasatinib therapy, particularly in patients with AP or BP disease and low platelet counts. Appropriate clinical monitoring and the timely interruption of dasatinib therapy are warranted in this subset of patients. Cancer 2009. © 2009 American Cancer Society.